Philip Morris ROIC Has a $35.6 Billion Blind Spot

Philip Morris International trades at 22x forward earnings — more than double its former parent Altria and nearly triple British American Tobacco. The bull case: 41.5% of revenue now comes from smoke-free products. ZYN nicotine pouches shipped 880 million cans in 2025, up 37%. IQOS dominates Japan's heated tobacco market at 32% total share. This isn't your grandfather's tobacco company.

But the ROIC data tells a more complicated story. MetricDuck calculates PM's FY2025 ROIC at 34.5% — strong by any standard. Yet Altria, the "boring" domestic tobacco company, earns 44.8%. PM trades at twice the P/E for three-quarters the return on capital. But the MetricDuck data reveals a critical nuance: Altria's higher ROIC comes from a business where revenue is declining 2.5% annually, while PM's lower return reflects active investment in growth — 8.6% revenue CAGR over three years.

The FY2025 10-K, filed February 6, 2026, reveals the structural reasons: $28.1 billion in goodwill and intangibles from the $16 billion Swedish Match acquisition, an Americas segment earning just 10.4% operating margins while Europe delivers 41.9%, and $11.7 billion in trade receivable factoring that inflates reported cash flow. The transformation is real. The question is whether investors are paying a fair price for it.

A note on the headline number: that 7.3% revenue growth is less clean than it appears. MetricDuck's revenue quality score for PM is 7 out of 10. Stripping out currency and acquisition effects, organic revenue grew 6.5%. The 10-K decomposes the drivers explicitly: favorable combustible tobacco pricing (higher prices on declining volumes) plus higher smoke-free product volumes, "notwithstanding unfavorable mix and lower volumes for cigarettes." Translation: PM is raising prices on a shrinking cigarette business while growing a lower-margin smoke-free business. The top line grows, but the growth quality is mixed — pricing on decline plus volume on investment-heavy products. Compare to Altria's revenue quality score of 5 out of 10, where discount cigarette market share reached 32.2% (up 2.4 share points year-over-year) and smokeable revenue fell 3.6%.

Strip out the acquisition-driven capital, and PM's legacy tobacco business produces extraordinary returns. Include it, and you're paying 22x for a company still proving that $16 billion was well spent. Whether the premium holds depends on whether ZYN and IQOS can earn their way out of the goodwill.

The Negative Equity Problem: Why Most PM Metrics Are Meaningless

Philip Morris has negative $8.0 billion in stockholders' equity. This isn't a sign of financial distress — it's the result of $35.6 billion in cumulative share buybacks since the 2008 spinoff from Altria. The company has returned more cash to shareholders than it has earned in total retained profits.

This creates a measurement problem. Return on equity is -104.1%. Book value per share is -$4.74. The debt-to-equity ratio is literally undefined. These numbers belong in no analysis because they describe the company's financial engineering history, not its operating economics.

The right approach is an asset-based ROIC calculation that ignores the capital structure entirely and asks: what return does PM earn on its actual operating assets?

MetricDuck's calculation (see our complete ROIC methodology guide for the full framework): NOPAT of $11.96 billion divided by invested capital of $36.16 billion = 34.5% ROIC. This invested capital figure is computed from operating assets ($61.4B) minus non-operating assets ($7.8B) minus non-interest-bearing liabilities ($7.2B), avoiding the negative equity distortion completely.

Both DuPont components are trending positive. NOPAT margin's 8-quarter trend is +13.6 percentage points, driven by smoke-free gross margins reaching 69.5%. Capital turnover is climbing at +0.15x as revenue scales against the fixed goodwill base. The combination produced a TTM ROIC of 36.5% — above the 32.0% 8-quarter median.

The value creation signal: PM's ROIC of 34.5% versus its 3.62% cost of debt creates a 30.9 percentage point spread — meaning every dollar of debt-funded capital generates returns nearly ten times its cost. Interest coverage of 9.38x (up 23.4% year-over-year) confirms PM is comfortably servicing its $48.8 billion in total debt despite the leveraged capital structure.

The ROIIC of 60.6% (TTM) indicates that incremental capital deployed over the trailing twelve months generated strong returns. But the quarterly figure dropped to 11.8% — reflecting the lumpy nature of PM's $1.6B in annual capital expenditures and the timing of cash flow generation.

$16 Billion for ZYN: The Swedish Match Acquisition Under the Microscope

Philip Morris completed the $16 billion acquisition of Swedish Match in November 2022. It was a bet on a single product category: nicotine pouches, specifically ZYN.

The balance sheet impact was immediate and massive:

77.8% of PM's invested capital is goodwill and intangibles. The Americas segment alone carries $8.8 billion in goodwill — overwhelmingly from Swedish Match — plus $4.8 billion in non-amortizable intangible assets consisting primarily of the ZYN trademark.

ZYN's FY2025 performance: 879.6 million cans shipped, up 36.6% year-over-year. The broader Americas segment generated $4,854 million in revenue. But the segment's operating margin was only 10.4% — because it carries $556 million per year in amortization of IQOS US commercialization rights (reacquired from Altria in 2023, with 3 years of useful life remaining) plus heavy ZYN capacity and marketing investment.

"During the fourth quarter of 2025, PMI completed the sale of one business and classified as held-for-sale net assets of certain other businesses, primarily related to its consumer accessories products acquired as part of the Swedish Match AB acquisition in 2022. As a result, PMI recorded a pre-tax loss of $94 million."

PMI is already shedding non-core Swedish Match assets (lighters, matches) at a $94 million loss. This is housekeeping — but it confirms the acquisition's value was always concentrated in ZYN, not the diversified Swedish Match portfolio.

The question the ROIC data forces: was paying $16 billion for what is essentially a single nicotine pouch brand the right capital allocation decision?

Why does PM earn lower ROIC than Altria? Capex intensity tells the story: PM spends 4.5% of revenue on capital expenditures versus Altria's 1.28%. PM invests 3.5x more of every revenue dollar into physical assets — ZYN manufacturing buildout, IQOS device production, heated tobacco infrastructure. This isn't inefficiency; it's the cost of transformation. Altria harvests a mature domestic franchise. PM is building the next one.

Compare the invested capital math. MO holds $17.4 billion in invested capital — less than half of PM's $36.2 billion — yet produces NOPAT of $9.3 billion (TTM) versus PM's $12.0 billion. The incremental $18.8 billion in invested capital that PM carries (mostly Swedish Match goodwill) generates only $2.7 billion in incremental NOPAT. That's a 14.4% marginal return — well below PM's blended 34.5%.

The ZYN Paradox: Volume Up, Pricing Power Under Pressure

Q4 2025 was the quarter competition arrived — and the data already shows the damage.

ZYN US shipments grew 19% year-over-year in Q4, with offtake volume up 23%. Full-year nicotine pouch shipments hit 879.6 million cans globally, up 36.6%. PMI invested over $800 million in US manufacturing capacity to keep up with demand. The volume story is exceptional. And the category context explains the intensity: Altria's Q3 2025 10-Q discloses that nicotine pouches now represent 55.7% of the entire US oral tobacco category — up 11.1 share points year-over-year. This isn't a niche anymore. It's the majority category.

But the 8-K earnings data reveals what the volume story obscures: Americas segment adjusted operating income decreased 43.4% organically in Q4. Volumes grew 19%. Operating income collapsed 43%. This is not a hypothetical competitive risk — it is retrospective evidence that pricing power eroded in real time.

The unit economics tell the story. Using the Americas segment as a proxy (which includes ZYN, IQOS US, and legacy Swedish Match): $4,854M in FY revenue across 880M ZYN cans shipped = ~$5.52 per can in segment revenue. Operating income of $505M = ~$0.57 per can. But the IQOS US amortization charge alone is $556M/year = ~$0.63 per can — the amortization drag exceeds the operating profit per can. Strip out that amortization and the implied pre-amortization contribution is $1.20 per can. Add back the $100M in promotional spending ($0.11 per can) and ZYN's underlying contribution margin is closer to $1.31 per can.

The insight: the IQOS amortization cliff (~2028) is a larger catalyst for Americas profitability than ZYN market share defense. When the $556M annual charge expires, operating income per can roughly doubles without any improvement in competitive position. This is a date on the calendar, not a strategic bet.

BAT's FY2025 20-F reveals VELO Plus has scaled dramatically: US nicotine pouch volume surged 249% to 3.5 billion pouches — a 3.5x increase from 1.0 billion in FY2024 — with US revenue reaching £317 million (+297%). Globally, VELO shipped 12.2 billion pouches (+47.1%) for £1,165 million in revenue, capturing 33.4% volume share of the Modern Oral category across BTI's top markets — up 7.5 share points year-over-year. BAT also launched Velo Shift in 2025, offering an innovative pouch shape and hexagonal can design. A critical structural advantage: Velo Plus uses synthetic nicotine — a regulatory arbitrage that follows a different FDA pathway than ZYN's tobacco-derived nicotine. This means Velo Plus can market flavors and formulations that tobacco-derived products cannot.

The FDA's Tobacco Products Scientific Advisory Committee reviewed ZYN's Modified Risk Tobacco Product (MRTP) application on January 22, 2026. If granted, ZYN could market explicit reduced-risk claims versus cigarettes — a significant marketing moat. But VELO Plus doesn't need regulatory approval to grow. It just needs to be on the shelf.

The 8-K reports PM forecasts cigarette shipment volume will decline approximately 3% in 2026. ZYN is the growth engine — but Q4 2025 shows the engine is now running on volume, not pricing. If promotional spending scales linearly with VELO Plus and on! PLUS shelf presence, the category may be commoditizing faster than the MRTP moat can solidify.

The $11.7 Billion Cash Flow Illusion

Philip Morris reported $12.2 billion in operating cash flow for FY2025, matching the prior year's record. At first glance, cash generation is exceptional: a 30.1% OCF margin and capex coverage of 7.8x.

But the 10-K discloses that PM sold $11.7 billion in trade receivables through factoring arrangements during 2025 — explicitly "without recourse," meaning the credit risk transfers entirely to the purchasing financial institutions. Trade receivable factoring accelerates cash collection by selling invoices to third parties. Under GAAP, this flows through operating cash flow.

Context: PM's 218-day cash conversion cycle — driven by $11.5 billion in tobacco leaf inventory that requires extended aging — creates a structural need for working capital financing. Unlike a software company that collects cash before delivering the product, PM ships physical goods globally through government-regulated distribution channels. Factoring addresses a real business need, not a cosmetic one.

The implication: nearly all of PM's reported $12.2 billion OCF may reflect the timing benefit of factoring rather than purely organic cash generation. PM's OCF without factoring arrangements is not separately disclosed, but the scale is significant — the factoring amount is 96% of reported OCF.

A partial counter-argument: PM's cash conversion ratio of 1.08x means the company generates 8% more operating cash flow than GAAP net income even after all the noise. Over an 8-quarter median, this ratio holds at 1.11x. The factoring inflates the timing, but PM's underlying earnings quality converts to cash at above-average rates.

But model the counterfactual. If PM's cash conversion without factoring dropped to 0.6-0.7x (a reasonable estimate given the 218-day CCC), unfactored OCF would be approximately $7.2-8.4 billion. Dividends paid were $8.6 billion. Unfactored dividend coverage: roughly 0.84-0.97x — below 1.0x, meaning the dividend structurally requires factoring to sustain. This isn't a criticism: trade receivable factoring with investment-grade government-regulated distributors is among the safest forms of receivable monetization. But it means factoring is not optional treasury management for PM. It is structural infrastructure for the dividend.

The OCF payout ratio MetricDuck calculates is 70.5% for FY2025, which appears healthy. But the 8-quarter median of 48.0% and the Q2 2025 spike to an estimated 182% of FCF suggest that cash flow timing is more volatile than the annual figure implies.

PM's 2026 OCF guidance of approximately $13.5 billion likely assumes continued factoring at similar levels. This isn't unusual — and trade receivable factoring is a legitimate treasury management tool. But when evaluating the sustainability of PM's $8.6 billion annual dividend commitment, the factoring dependence matters.

Four Segments, Four Margins: Where PM Actually Makes Money

PM's four operating segments tell the story of a company mid-transformation. The mature international businesses generate extraordinary margins. The Americas buildout consumes capital.

The contrast is stark. East Asia, Australia and Global Travel Retail earns 47.1% operating margins — driven by IQOS's dominant position in Japan (32.1% total market share, approximately 70% of the heat-not-burn category). Europe earns 41.9%. These are world-class margins for any consumer goods company.

A milestone buried in the segment revenue note: Americas smoke-free revenue ($2,691M) now exceeds Americas combustible revenue ($2,163M). The Americas business is already majority smoke-free by revenue — a structural crossover that validates the Swedish Match thesis even as margins remain depressed.

The Americas at 10.4% pulls the blended company margin down by 3-4 percentage points. Three factors depress Americas margins:

1. IQOS reacquired rights amortization: $556 million per year, with only 3 years remaining. PMI paid approximately $2.8 billion to reacquire IQOS US commercialization rights from Altria — this non-cash charge mechanically depresses margins.

2. ZYN capacity buildout: Over $800 million invested in manufacturing infrastructure, primarily the Owensboro, Kentucky expansion. These costs flow through before the full revenue benefit materializes.

3. ZYN promotional spending: Approximately $100 million to defend market share against VELO Plus and on! PLUS — an expense that didn't exist two years ago.

The bull case for PM hinges on Americas margin expansion. When the IQOS amortization expires around 2028, that's $556 million in annual expense that simply disappears. If ZYN reaches manufacturing scale and promotional spending normalizes, Americas margins could converge toward 25-30%, adding several percentage points to blended ROIC.

One critical risk: Russia. The SSEA, CIS & MEA segment includes $4.8 billion in Russian assets, including $2.3 billion in cash denominated in rubles. Russia accounts for approximately 9% of total shipment volumes. Divestiture would likely involve material impairment charges. The 10-K risk landscape assessment rates geopolitical risk as "high" and "escalated."

PM at 22x vs Altria at 11x: Is the Premium Justified?

The ROIC comparison against PM's closest peer is not flattering:

Altria earns a higher ROIC (44.8% vs 34.5%) at nearly twice the NOPAT margin (41.1% vs 29.4%). Its capital-light model — no international operations, no $16 billion acquisitions — produces exceptional returns on a modest invested capital base. The market charges half the price for it.

But here's what the simple ROIC comparison misses: PM earns higher gross margins than Altria — 67.1% vs 62.0%. The ROIC gap is entirely explained by Swedish Match acquisition goodwill and transformation-era capex, not operating weakness. PM's underlying product economics are superior.

And Altria's higher ROIC masks a deteriorating business at multiple levels. MetricDuck's filing intelligence assigns MO a health score of 4/10 — below PM's 5/10 — with a revenue quality score of just 5/10 (versus PM's 7/10) and an accounting aggressiveness label of "aggressive" (versus PM's "neutral"). The evidence is specific: Altria's smokeable products revenue declined 3.6% as discount cigarette market share surged to 32.2% — up 2.4 share points year-over-year — a structural shift as inflation-pressured consumers trade down from premium brands. The acceleration is alarming: Altria's own 10-Q discloses that total US cigarette industry volume declined approximately 8% in Q3 2025 versus Q3 2024 — far faster than PM's -3% international guidance. Altria's own filing acknowledges "discretionary income pressures" and "evolving adult tobacco consumer preferences."

Altria's smoke-free transformation is also further behind than PM's — and already failing. MO acquired NJOY for $2.75 billion in June 2023 and wrote down $873 million in e-vapor goodwill by September 2025 — a 32% impairment in 27 months. The trigger was specific: the U.S. International Trade Commission issued an exclusion order in January 2025 banning NJOY ACE from the US market effective March 31, 2025 — and Altria still potentially owes up to $250 million more in contingent payments tied to pending FDA authorizations for NJOY flavored products. Add the $354 million Skoal trademark impairment in oral tobacco (their core business), and Altria's non-recurring charges totaled $1.05 billion in just nine months — larger than PM's $999M for the full year. Historical tobacco litigation payments exceed $1.1 billion with zero currently accrued. MO's on! PLUS nicotine pouches grew oral tobacco revenue just 0.58% — barely moving the needle against ZYN's 36.6% growth. Revenue is declining at -2.5% YoY while PM is growing at a 3-year CAGR of 8.6%.

The framing matters: Altria's higher ROIC reflects a capital-light model harvesting a shrinking revenue base. PM's lower ROIC reflects a capital-heavy transformation bet on a growing one. PM is paying for growth with capital. Altria is extracting from a declining franchise.

PM's premium rests on whether that growth materializes. Smoke-free products now represent 41.5% of revenue and grew 15.0% organically in FY2025. If IQOS and ZYN continue their trajectory, PM's revenue mix will eventually be majority smoke-free, justifying a consumer tech multiple rather than a tobacco multiple.

But BTI returned 56.8% in the past year. BAT's VELO Plus is no longer "gaining traction" — it has arrived. The FY2025 20-F shows smokeless revenue now represents 25% of BAT's total (up from 21.5% in FY2024), with New Categories hitting a 25% contribution margin at constant currency. VELO Plus US revenue quadrupled from £80M to £317M in one year. Vuse revenue declined 10.4% globally, but showed encouraging signs of recovery in the US second half with the launch of Vuse Ultra, a premium connected device. BTI trades at 9.3x forward earnings — a fraction of PM's 22x. Notably, PM and BTI settled all patent infringement litigation in February 2024 — the current nicotine pouch battle is happening in a post-settlement environment where both companies compete commercially without patent friction.

Jefferies downgraded PM from Buy to Hold on January 20, 2026, citing valuation. The analyst consensus implies PM needs to sustain 7-9% organic operating income growth for several years to justify the multiple. That's exactly what PM's 2026-2028 growth algorithm targets.

The dividend question. Income investors evaluating PM versus MO should look at the FCF math. PM pays $5.64 per share annually (CAGR5: 3.5%) and generated $10.7 billion in FCF against $8.6 billion in dividends — a 1.24x FCF coverage ratio. That's adequate but thin. Altria's FCF covers its dividend at 1.70x. On an AFFO basis (which includes maintenance capex), PM's payout ratio is 76.2% — sustainable at current earnings levels but leaving limited room for dividend growth acceleration. Investors seeking pure income at maximum safety should prefer MO's 6.4% yield with 1.70x coverage. PM's 3.5% yield is a growth bet with a dividend attached.

The risk that's underpriced: EU regulatory. The European Commission is considering restrictions on nicotine pouches under TPD3, delayed to mid-2026. France has already banned them outright. A broad EU ban would cap ZYN's European growth vector — a scenario not reflected in the current valuation.

What Determines Whether $16 Billion Was Worth It

The Swedish Match acquisition will ultimately be judged on three questions that can't be answered from a single 10-K:

1. Can ZYN maintain pricing power? Q4 2025 showed the first cracks — volumes growing while promotional spending surged. If the nicotine pouch category becomes a volume game rather than a pricing game, ZYN's economics deteriorate. The MRTP decision is the swing factor: approval gives ZYN a marketing moat that competitors can't match.

2. Will IQOS ILUMA get FDA authorization? PMI is currently selling the older IQOS 3 Duo in the US while consumers in Japan and Europe already use the superior ILUMA. The FDA review has been pending for nearly two years. Without ILUMA, the US heated tobacco market can't reach the penetration levels seen in Japan (32% share).

3. When does the Americas segment inflect? 2026 guidance calls for organic revenue growth of 5-7% and organic operating income growth of 7-9%. The company targets adjusted diluted EPS of $8.39-$8.54. If Americas margins expand as the IQOS amortization ($556M/year) begins to wind down and ZYN reaches scale, the ROIC inflection could be significant. Notably, PM is splitting into "International" and "U.S." business units starting in Q4 2025 — making the Americas trajectory more visible and accountable in future reporting.

PM's management expressed confidence. CEO Jacek Olczak stated: "We achieved another remarkable year of results in 2025, with a fifth consecutive year of volume growth, net revenues surpassing $40 billion, and very good operating margin expansion." The company has delivered its three-year CAGR targets on operating income and EPS in just two years.

The 10-K filing intelligence also flags nearly $1 billion in non-recurring charges across FY2025: a $176 million Germany excise tax classification charge, a $94 million loss on Swedish Match consumer accessories disposal, a $204 million South Korea indirect tax charge, $45 million Egypt sales tax, and others. Earnings quality score: 6/10.

MetricDuck's automated analysis tags the Germany excise ($176M), South Korea indirect tax ($204M), Egypt sales tax ($45M), and Ukraine-related charges ($53M) as "may recur" — meaning they stem from ongoing regulatory disputes or geopolitical conditions rather than truly one-time events. Crucially, these charges cluster in PM's highest-margin segments: Germany excise hits Europe (41.9% margin), Egypt and Ukraine hit SSEA/CIS/MEA (34.0% margin). The segments with the best-looking margins carry the most regulatory tax risk. If these charges truly recur — and the multi-year pattern suggests they will — adjusted Europe margins are closer to 40% and SSEA closer to 33%.

The pattern of approximately $1 billion in "non-recurring" charges appearing annually (2023: $680M goodwill impairment; 2024: various; 2025: $999M net) suggests these are effectively operating costs under another name. Investors using adjusted EPS should discount PM's $7.54 adjusted figure by roughly $0.40-$0.60 per share to account for the persistent drag.

PM's smoke-free transformation is real, accelerating, and well-executed. The question was never whether it's happening. The question is whether 22x is the right price for a company earning lower returns on capital than the competitor you can buy at 11x.

Frequently Asked Questions

What is Philip Morris International's ROIC?

PM's FY2025 ROIC is 34.5%, calculated as NOPAT of $11.96 billion divided by invested capital of $36.16 billion using an asset-based formula. Traditional equity-based ROIC is meaningless for PM due to negative $8 billion in stockholders' equity from $35.6 billion in cumulative buybacks. The asset-based approach strips out the noise from financial engineering and measures the actual return on operating assets.

Why does Philip Morris have negative equity?

PM has negative stockholders' equity of approximately -$8.0 billion because it has repurchased $35.6 billion in treasury stock since its 2008 spinoff from Altria — exceeding accumulated retained earnings. This makes ROE (-104%), book value per share (-$4.74), and debt-to-equity ratio completely meaningless. It does not indicate financial distress — PM generated $12.2 billion in operating cash flow in FY2025.

Was the Swedish Match acquisition worth it?

The $16 billion acquisition added $8.8 billion in goodwill and $4.8 billion in non-amortizable intangibles (primarily ZYN trademarks). ZYN shipped 880 million cans in FY2025 (+36.6%), but the Americas segment earned only 10.4% operating margins due to $556M/year in IQOS rights amortization and heavy investment spending. The full return won't be visible until amortization rolls off around 2028.

What is trade receivable factoring and how does it affect PM's cash flow?

PM sold $11.7 billion in trade receivables through factoring arrangements during FY2025 — explicitly "without recourse." This is legally valid under GAAP and classified as operating cash flow, but it means PM's reported $12.2 billion OCF includes significant cash acceleration. Dividends paid were $8.6 billion, and unfactored dividend coverage may be below 1.0x, meaning factoring is structural infrastructure for the dividend, not optional treasury management.

How does Philip Morris compare to Altria?

Altria earns 44.8% ROIC on $17.4 billion in invested capital versus PM's 34.5% on $36.2 billion. But Altria's higher ROIC reflects a capital-light domestic franchise with revenue declining -2.5% annually, while PM's lower return reflects active investment in growth (8.6% revenue CAGR). PM trades at 22x forward earnings versus Altria's ~11x — the premium is justified only if PM's smoke-free transformation eventually produces returns exceeding Altria's mature model.

Methodology

Data Sources

This analysis uses MetricDuck's quantitative metrics (ROIC, DuPont decomposition, ROIIC, cash flow ratios) calculated from Philip Morris International's XBRL-tagged SEC filings. Filing intelligence extracted via MetricDuck's 5-pass comprehensive analysis of the FY2025 10-K (filed February 6, 2026) and Q4 2025 8-K earnings release. Altria (MO) peer data from MetricDuck's metrics pipeline (latest available: Q3 2025 10-Q). Segment data, volume figures, and trade receivable factoring details sourced directly from PM's FY2025 10-K.

Limitations

• ZYN-specific margins are not separately disclosed. Americas segment margins are used as a proxy, but this segment includes IQOS US operations and legacy Swedish Match businesses.
• Trade receivable factoring impact on operating cash flow is not disclosed on a net basis. The $11.7 billion figure represents the gross amount of receivables sold, not the incremental cash flow benefit.
• Altria comparison uses the latest available MetricDuck data (Q3 2025) while PM figures reflect FY2025. MO's FY2025 10-K has not yet been processed.
• BTI (British American Tobacco) files as a foreign private issuer using 20-F format without XBRL-tagged financials, limiting MetricDuck's quantitative comparison. BTI valuation figures are from third-party sources.

Disclaimer

This analysis is for informational purposes only and does not constitute investment advice. The author does not hold positions in PM, MO, or BTI. Past performance and current metrics do not guarantee future results. All data is derived from public SEC filings and may contain errors or omissions from the automated extraction process.